Published: 30 Apr 2023 | Report Code: 10248437 | Pages: 178
North America Clinical Trials Market is projected to grow by 7.1% annually in the forecast period and reach $39,268.7 million by 2031, driven by the increasing number of clinical trials and increase in demand for novel therapies, rising prevalence of chronic diseases such as cancer and diabetes, the outbreak of tropical and infectious diseases such as COVID-19, and the increase in government initiatives and R&D investments. Highlighted with 89 tables and 75 figures, this 178-page report “North America Clinical Trials Market 2022-2031 by Product Category (Drugs, Devices, Procedures), Phase (I, II, III, IV), Design (Interventional, Observational, Expanded Access), Service Type (Site Identification, Lab Services, Supply & Logistic, Decentralized Services), Indication (Oncology, Infectious Diseases, Cardiology, Obesity, Diabetes, Neurology), End User, and Country: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire North America Clinical Trials Market and all its sub-segments through extensively detailed classifications.
Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2021-2022 and provides forecast from 2023 till 2031 with 2022 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
In-depth qualitative analyses include the identification and investigation of the following aspects:
• Market Structure
• Growth Drivers
• Restraints and Challenges
• Emerging Product Trends & Market Opportunities
• Porter’s Five Forces
The trend and outlook of North America market is forecast in an optimistic, balanced, and conservative view by taking into account of COVID-19 and the Russia-Ukraine conflict. The balanced (most likely) projection is used to quantify North America clinical trials market in every aspect of the classification from perspectives of Product Category, Phase, Design, Service Type, Indication, End User, and Country.
Based on Product Category, the North America market is segmented into the following sub-markets with annual revenue ($ mn) for 2022-2031 included in each section.
• Trials of Drugs
o Small Molecule Drugs
o Vaccines
o Cell & Gene Therapy
o Other Drugs
• Trials of Devices
• Trials of Procedures
Based on Phase, the North America market is segmented into the following sub-markets with annual revenue ($ mn) for 2022-2031 included in each section.
• Phase I
• Phase II
• Phase III
• Phase IV
By Design, the North America market is segmented into the following sub-markets with annual revenue ($ mn) for 2022-2031 included in each section.
• Interventional Studies
o Randomized Control Trial
o Adaptive Clinical Trial
o Non-randomized Control Trial
• Observational Studies
o Cohort Study
o Case Control Study
o Cross Sectional Study
o Ecological Study
• Expanded Access Trials
By Service Type, the North America market is segmented into the following sub-markets with annual revenue ($ mn) for 2022-2031 included in each section.
• Protocol Designing
• Site Identification
• Patient Recruitment
• Laboratory Services
• Bioanalytical Testing Services
• Clinical Trial Data Management Services
• Clinical Trial Supply & Logistic Services
• Decentralized Clinical Trial Services
• Medical Device Testing Services
• Other Clinical Trial Services
By Indication, the North America market is segmented into the following sub-markets with annual revenue ($ mn) for 2022-2031 included in each section.
• Oncology
• Infectious Diseases
• Cardiology
• Obesity
• Diabetes
• Neurology
• Immunology
• Pain Management
• Other Indications
By End User, the North America market is segmented into the following sub-markets with annual revenue ($ mn) for 2022-2031 included in each section.
• Pharmaceutical and Biotechnological Companies
• Clinical Research Organizations
• Clinical Testing Laboratories
• Other End Users
Geographically, the following national/local markets are fully investigated:
• U.S.
• Canada
• Mexico
For each key country, detailed analysis and data for annual revenue ($ mn) are available for 2022-2031. The breakdown of each national market by Phase, Design, and Indication over the forecast years are also included. The report also covers the current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.
Selected Key Players:
Accell Clinical Research LLC
Charles River Laboratories
ClinDatrix Inc
Clinipace
Eli Lilly and Company
F. Hoffmann-La Roche Ltd.
ICON PLC
IQVIA Holdings, Inc.
Laboratory Corporation of America (Covance Inc.)
Novo Nordisk AS
PAREXEL International Corporation
Pfizer Inc.
Pharmaceutical Product Development LLC
PhlexNorth America
PRA Health Sciences
Sanofi SA
SGS SA (SGS Life Sciences)
Syneos Health Inc.
Wuxi AppTec Inc.
(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
Table of Contents: 1 Introduction 9 1.1 Industry Definition and Research Scope 9 1.1.1 Industry Definition 9 1.1.2 Research Scope 10 1.2 Research Methodology 13 1.2.1 Overview of Market Research Methodology 13 1.2.2 Market Assumption 14 1.2.3 Secondary Data 14 1.2.4 Primary Data 14 1.2.5 Data Filtration and Model Design 15 1.2.6 Market Size/Share Estimation 16 1.2.7 Research Limitations 17 1.3 Executive Summary 18 2 Market Overview and Dynamics 21 2.1 Market Size and Forecast 21 2.1.1 Impact of COVID-19 on World Economy 23 2.1.2 Impact of COVID-19 on the Market 26 2.1.3 Impact of Russia-Ukraine Conflict: War Slows Economic Recovery 28 2.2 Major Growth Drivers 32 2.3 Market Restraints and Challenges 39 2.4 Emerging Opportunities and Market Trends 42 2.5 Porter’s Fiver Forces Analysis 46 3 Segmentation of North America Market by Product Category 50 3.1 Market Overview by Product Category 50 3.2 Trials of Drugs 52 3.2.1 Small Molecule Drugs 53 3.2.2 Vaccines 54 3.2.3 Cell & Gene Therapy 55 3.2.4 Other Drugs 56 3.3 Trials of Devices 57 3.4 Trials of Procedures 58 4 Segmentation of North America Market by Phase 59 4.1 Market Overview by Phase 59 4.2 Phase I 61 4.3 Phase II 62 4.4 Phase III 63 4.5 Phase IV 64 5 Segmentation of North America Market by Design 65 5.1 Market Overview by Design 65 5.2 Interventional Studies 67 5.2.1 Randomized Control Trial 69 5.2.2 Adaptive Clinical Trial 70 5.2.3 Non-randomized Control Trial 71 5.3 Observational Studies 72 5.3.1 Cohort Study 74 5.3.2 Case Control Study 75 5.3.3 Cross Sectional Study 76 5.3.4 Ecological Study 77 5.4 Expanded Access Trials 78 6 Segmentation of North America Market by Service Type 79 6.1 Market Overview by Service Type 79 6.2 Protocol Designing 81 6.3 Site Identification 82 6.4 Patient Recruitment 83 6.5 Laboratory Services 84 6.6 Bioanalytical Testing Services 85 6.7 Clinical Trial Data Management Services 86 6.8 Clinical Trial Supply & Logistic Services 87 6.9 Decentralized Clinical Trial Services 88 6.10 Medical Device Testing Services 89 6.11 Other Clinical Trial Services 90 7 Segmentation of North America Market by Indication 91 7.1 Market Overview by Indication 91 7.2 Oncology 93 7.3 Infectious Diseases 94 7.4 Cardiology 95 7.5 Obesity 96 7.6 Diabetes 97 7.7 Neurology 98 7.8 Immunology 99 7.9 Pain Management 100 7.10 Other Indications 101 8 Segmentation of North America Market by End User 102 8.1 Market Overview by End User 102 8.2 Pharmaceutical and Biotechnological Companies 104 8.3 Clinical Research Organizations 105 8.4 Clinical Testing Laboratories 106 8.5 Other End Users 107 9 North America Market 2021-2031 by Country 108 9.1 Overview of North America Market 108 9.2 U.S. 111 9.3 Canada 114 9.4 Mexico 116 10 Competitive Landscape 118 10.1 Overview of Key Vendors 118 10.2 New Product Launch, Partnership, Investment, and M&A 122 10.3 Company Profiles 123 Accell Clinical Research LLC 123 Charles River Laboratories 125 ClinDatrix Inc 128 Clinipace 129 Eli Lilly and Company 131 F. Hoffmann-La Roche Ltd. 134 ICON PLC 137 IQVIA Holdings, Inc. 140 Laboratory Corporation of America (Covance Inc.) 144 Novo Nordisk AS 148 PAREXEL International Corporation 151 Pfizer Inc. 155 Pharmaceutical Product Development LLC 160 Phlexglobal 163 PRA Health Sciences 165 Sanofi SA 167 SGS SA (SGS Life Sciences) 170 Syneos Health Inc. 173 Wuxi AppTec Inc. 176 RELATED REPORTS 178
List of Tables: Table 1. Snapshot of North America Clinical Trials Market in Balanced Perspective, 2022-2031 19 Table 2. Total Number of Registered Clinical Studies Worldwide, 2010-2021 22 Table 3. World Economic Outlook, 2021-2031 24 Table 4. World Economic Outlook, 2021-2023 25 Table 5. Scenarios for Economic Impact of Ukraine Crisis 29 Table 6. World Health Spending by Region, $ bn, 2013-2020 38 Table 7. Main Product Trends and Market Opportunities in North America Clinical Trials Market 42 Table 8. North America Clinical Trials Market by Product Category, 2021-2031, $ mn 50 Table 9. North America Clinical Trials Market: Trials of Drugs by Drug Type, 2021-2031, $ mn 52 Table 10. North America Clinical Trials Market by Phase, 2021-2031, $ mn 59 Table 11. North America Clinical Trials Market by Design, 2021-2031, $ mn 65 Table 12. North America Clinical Trials Market: Interventional Studies by Segment, 2021-2031, $ mn 68 Table 13. North America Clinical Trials Market: Observational Studies by Segment, 2021-2031, $ mn 73 Table 14. North America Clinical Trials Market by Service Type, 2021-2031, $ mn 79 Table 15. North America Clinical Trials Market by Indication, 2021-2031, $ mn 91 Table 16. North America Clinical Trials Market by End User, 2021-2031, $ mn 102 Table 17. North America Clinical Trials Market by Country, 2021-2031, $ mn 109 Table 18. U.S. Clinical Trials Market by Phase, 2021-2031, $ mn 113 Table 19. U.S. Clinical Trials Market by Design, 2021-2031, $ mn 113 Table 20. U.S. Clinical Trials Market by Indication, 2021-2031, $ mn 113 Table 21. Canada Clinical Trials Market by Phase, 2021-2031, $ mn 115 Table 22. Canada Clinical Trials Market by Design, 2021-2031, $ mn 115 Table 23. Canada Clinical Trials Market by Indication, 2021-2031, $ mn 115 Table 24. Mexico Clinical Trials Market by Phase, 2021-2031, $ mn 117 Table 25. Mexico Clinical Trials Market by Design, 2021-2031, $ mn 117 Table 26. Mexico Clinical Trials Market by Indication, 2021-2031, $ mn 117 Table 27. Percentage of Registered Studies by Location (as of February 24, 2022) 120 Table 28. Percentage of Recruiting Studies by Location (as of February 24, 2022) 120 Table 29. Accell Clinical Research LLC: Company Snapshot 123 Table 30. Accell Clinical Research LLC: Business Segmentation 124 Table 31. Accell Clinical Research LLC: Product Portfolio 124 Table 32. Charles River Laboratories: Company Snapshot 125 Table 33. Charles River Laboratories: Product Portfolio 126 Table 34. Charles River Laboratories: Breakdown of Revenue by Division 126 Table 35. Charles River Laboratories: Breakdown of Revenue by Region 127 Table 36. ClinDatrix Inc: Company Snapshot 128 Table 37. Clinipace: Company Snapshot 129 Table 38. Clinipace: Product Portfolio 130 Table 39. Eli Lilly and Company: Company Snapshot 131 Table 40. Eli Lilly and Company: Pharmaceutical Brands 132 Table 41. Eli Lilly and Company: Clinical Trial Service 132 Table 42. Eli Lilly and Company: Breakdown of Revenue by Therapeutic Area 132 Table 43. Eli Lilly and Company: Breakdown of Revenue by Region 133 Table 44. F. Hoffmann-La Roche: Company Snapshot 134 Table 45. F. Hoffmann-La Roche: Clinical Trial Service 134 Table 46. F. Hoffmann-La Roche: Business Segmentation 135 Table 47. F. Hoffmann-La Roche: Revenue by Region 135 Table 48. ICON Plc: Company Snapshot 137 Table 49. ICON Plc: Business Segmentation 137 Table 50. ICON Plc: Product Portfolio 138 Table 51. ICON Plc: Revenue by Region, 2020, 8 Table 52. IQVIA Holdings Inc.: Company Snapshot 140 Table 53. IQVIA Holdings Inc.: Business Segmentation 141 Table 54. IQVIA Holdings Inc.: Revenue by Region, 2020, 1 Table 55. IQVIA Holdings Inc.: Product Portfolio 142 Table 56. Covance Inc.: Company Snapshot 144 Table 57. Covance Inc.: Product Portfolio 145 Table 58. Covance Inc.: Revenue by Region, 2020, 6 Table 59. Novo Nordisk: Company Snapshot 148 Table 60. Novo Nordisk: Product Portfolio 149 Table 61. Novo Nordisk: Breakdown of Revenue by Business Segment 150 Table 62. Novo Nordisk: Breakdown of Revenue by Region 150 Table 63. PAREXEL International Corporation: Company Snapshot 151 Table 64. PAREXEL International Corporation: Business Segmentation 152 Table 65. PAREXEL International Corporation: Revenue by Region, 2018, 2 Table 66. PAREXEL International Corporation: Product Portfolio 153 Table 67. Pfizer Inc.: Company Snapshot 155 Table 68. Pfizer Inc.: Business Segmentation 156 Table 69. Pfizer Inc.: Breakdown of Revenue by Product Category 156 Table 70. Pfizer Inc.: Breakdown of Revenue by Region 157 Table 71. Pfizer Inc.: Product Portfolio 157 Table 72. Pfizer Inc.: Revenue, 2018-2020, $ bn 158 Table 73. Pharmaceutical Product Development LLC (PPD): Company Snapshot 160 Table 74. Pharmaceutical Product Development LLC (PPD): Breakdown of Revenue by Division 161 Table 75. Pharmaceutical Product Development LLC (PPD): Breakdown of Revenue by Region 161 Table 76. Phlexglobal: Company Snapshot 163 Table 77. PRA Health Sciences Inc.: Company Snapshot 165 Table 78. PRA Health Sciences Inc.: Business Segmentation 166 Table 79. PRA Health Sciences Inc.: Revenue by Region, 2018, 6 Table 80. Sanofi: Company Snapshot 167 Table 81. Sanofi: Business Segmentation 168 Table 82. Sanofi: Breakdown of Revenue by Region 168 Table 83. SGS SA (SGS Life Sciences): Company Snapshot 170 Table 84. SGS SA (SGS Life Sciences): Business Segmentation 171 Table 85. SGS SA (SGS Life Sciences): Revenue by Region, 2018, 1 Table 86. Syneos Health Inc.: Company Snapshot 173 Table 87. Syneos Health Inc.: Business Segmentation 174 Table 88. Syneos Health Inc.: Revenue by Region, 2020, 4 Table 89. WuXi AppTec Inc.: Company Snapshot 176
List of Figures: Figure 1. Research Method Flow Chart 13 Figure 2. Bottom-up Approach and Top-down Approach for Market Estimation 16 Figure 3. North America Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2022-2031 18 Figure 4. North America Clinical Trials Market, 2021-2031, $ mn 21 Figure 5. Impact of COVID-19 on Business 26 Figure 6. Primary Drivers and Impact Factors of North America Clinical Trials Market 32 Figure 7. Percentage of Trial Participants by Country, 2015-2019 35 Figure 8. Leading Causes of Death in the World, 2000 and 2019, million 36 Figure 9. Worldwide Geriatric Population (60 years and above) by Regions, 2015 & 2030, million 37 Figure 10. World Population 65 and Over, % of Total Population, 1950-2060 37 Figure 11. Primary Restraints and Impact Factors of North America Clinical Trials Market 39 Figure 12. Investment Opportunity Analysis 43 Figure 13. Porter’s Fiver Forces Analysis of North America Clinical Trials Market 46 Figure 14. Breakdown of North America Clinical Trials Market by Product Category, 2021-2031, % of Revenue 51 Figure 15. North America Addressable Market Cap in 2023-2031 by Product Category, Value ($ mn) and Share (%) 51 Figure 16. North America Clinical Trials Market by Product Category: Trials of Drugs, 2021-2031, $ mn 52 Figure 17. North America Clinical Trials Market by Trials of Drugs: Small Molecule Drugs, 2021-2031, $ mn 53 Figure 18. North America Clinical Trials Market by Trials of Drugs: Vaccines, 2021-2031, $ mn 54 Figure 19. North America Clinical Trials Market by Trials of Drugs: Cell & Gene Therapy, 2021-2031, $ mn 55 Figure 20. North America Clinical Trials Market by Trials of Drugs: Other Drugs, 2021-2031, $ mn 56 Figure 21. North America Clinical Trials Market by Product Category: Trials of Devices, 2021-2031, $ mn 57 Figure 22. North America Clinical Trials Market by Product Category: Trials of Procedures, 2021-2031, $ mn 58 Figure 23. Breakdown of North America Clinical Trials Market by Phase, 2021-2031, % of Sales Revenue 60 Figure 24. North America Addressable Market Cap in 2023-2031 by Phase, Value ($ mn) and Share (%) 60 Figure 25. North America Clinical Trials Market by Phase: Phase I, 2021-2031, $ mn 61 Figure 26. North America Clinical Trials Market by Phase: Phase II, 2021-2031, $ mn 62 Figure 27. North America Clinical Trials Market by Phase: Phase III, 2021-2031, $ mn 63 Figure 28. North America Clinical Trials Market by Phase: Phase IV, 2021-2031, $ mn 64 Figure 29. Breakdown of North America Clinical Trials Market by Design, 2021-2031, % of Sales Revenue 66 Figure 30. North America Addressable Market Cap in 2023-2031 by Design, Value ($ mn) and Share (%) 66 Figure 31. North America Clinical Trials Market by Design: Interventional Studies, 2021-2031, $ mn 67 Figure 32. North America Clinical Trials Market by Interventional Studies: Randomized Control Trial, 2021-2031, $ mn 69 Figure 33. North America Clinical Trials Market by Interventional Studies: Adaptive Clinical Trial, 2021-2031, $ mn 70 Figure 34. North America Clinical Trials Market by Interventional Studies: Non-randomized Control Trial, 2021-2031, $ mn 71 Figure 35. North America Clinical Trials Market by Design: Observational Studies, 2021-2031, $ mn 72 Figure 36. North America Clinical Trials Market by Observational Studies: Cohort Study, 2021-2031, $ mn 74 Figure 37. North America Clinical Trials Market by Observational Studies: Case Control Study, 2021-2031, $ mn 75 Figure 38. North America Clinical Trials Market by Observational Studies: Cross Sectional Study, 2021-2031, $ mn 76 Figure 39. North America Clinical Trials Market by Observational Studies: Ecological Study, 2021-2031, $ mn 77 Figure 40. North America Clinical Trials Market by Design: Expanded Access Trials, 2021-2031, $ mn 78 Figure 41. Breakdown of North America Clinical Trials Market by Service Type, 2021-2031, % of Revenue 80 Figure 42. North America Addressable Market Cap in 2023-2031 by Service Type, Value ($ mn) and Share (%) 80 Figure 43. North America Clinical Trials Market by Service Type: Protocol Designing, 2021-2031, $ mn 81 Figure 44. North America Clinical Trials Market by Service Type: Site Identification, 2021-2031, $ mn 82 Figure 45. North America Clinical Trials Market by Service Type: Patient Recruitment, 2021-2031, $ mn 83 Figure 46. North America Clinical Trials Market by Service Type: Laboratory Services, 2021-2031, $ mn 84 Figure 47. North America Clinical Trials Market by Service Type: Bioanalytical Testing Services, 2021-2031, $ mn 85 Figure 48. North America Clinical Trials Market by Service Type: Clinical Trial Data Management Services, 2021-2031, $ mn 86 Figure 49. North America Clinical Trials Market by Service Type: Clinical Trial Supply & Logistic Services, 2021-2031, $ mn 87 Figure 50. North America Clinical Trials Market by Service Type: Decentralized Clinical Trial Services, 2021-2031, $ mn 88 Figure 51. North America Clinical Trials Market by Service Type: Medical Device Testing Services, 2021-2031, $ mn 89 Figure 52. North America Clinical Trials Market by Service Type: Other Clinical Trial Services, 2021-2031, $ mn 90 Figure 53. Breakdown of North America Clinical Trials Market by Indication, 2021-2031, % of Revenue 92 Figure 54. North America Addressable Market Cap in 2023-2031 by Indication, Value ($ mn) and Share (%) 92 Figure 55. North America Clinical Trials Market by Indication: Oncology, 2021-2031, $ mn 93 Figure 56. North America Clinical Trials Market by Indication: Infectious Diseases, 2021-2031, $ mn 94 Figure 57. North America Clinical Trials Market by Indication: Cardiology, 2021-2031, $ mn 95 Figure 58. North America Clinical Trials Market by Indication: Obesity, 2021-2031, $ mn 96 Figure 59. North America Clinical Trials Market by Indication: Diabetes, 2021-2031, $ mn 97 Figure 60. North America Clinical Trials Market by Indication: Neurology, 2021-2031, $ mn 98 Figure 61. North America Clinical Trials Market by Indication: Immunology, 2021-2031, $ mn 99 Figure 62. North America Clinical Trials Market by Indication: Pain Management, 2021-2031, $ mn 100 Figure 63. North America Clinical Trials Market by Indication: Other Indications, 2021-2031, $ mn 101 Figure 64. Breakdown of North America Clinical Trials Market by End User, 2021-2031, % of Revenue 102 Figure 65. North America Addressable Market Cap in 2023-2031 by End User, Value ($ mn) and Share (%) 103 Figure 66. North America Clinical Trials Market by End User: Pharmaceutical and Biotechnological Companies, 2021-2031, $ mn 104 Figure 67. North America Clinical Trials Market by End User: Clinical Research Organizations, 2021-2031, $ mn 105 Figure 68. North America Clinical Trials Market by End User: Clinical Testing Laboratories, 2021-2031, $ mn 106 Figure 69. North America Clinical Trials Market by End User: Other End Users, 2021-2031, $ mn 107 Figure 70. Breakdown of North America Clinical Trials Market by Country, 2022 and 2031, % of Revenue 109 Figure 71. Contribution to North America 2023-2031 Cumulative Market by Country, Value ($ mn) and Share (%) 110 Figure 72. U.S. Clinical Trials Market, 2021-2031, $ mn 112 Figure 73. Canada Clinical Trials Market, 2021-2031, $ mn 114 Figure 74. Clinical Trials Market in Mexico, 2021-2031, $ mn 116 Figure 75. Growth Stage of North America Clinical Trials Industry over the Forecast Period 118
Selected Key Players: Accell Clinical Research LLC Charles River Laboratory ClinDatrix Inc Clinipace Eli Lilly and Company F. Hoffmann-La Roche Ltd. ICON PLC IQVIA Holdings, Inc. Laboratory Corporation of America Novo Nordisk AS PAREXEL International Corporation Pfizer Inc. Pharmaceutical Product Development LLC PRA Health Sciences Sanofi SA SGS SA Syneos Health Inc. Wuxi AppTec Inc. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)